Dr Joseph L Galkowski, DO | |
3015 N Ballas Rd, Dept Emergency Med, Saint Louis, MO 63131-2329 | |
(314) 966-5000 | |
(314) 747-3338 |
Full Name | Dr Joseph L Galkowski |
---|---|
Gender | Male |
Speciality | Emergency Medicine |
Experience | 30 Years |
Location | 3015 N Ballas Rd, Saint Louis, Missouri |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194707612 | NPI | - | NPPES |
249809112 | Medicaid | MO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 106567 (Missouri) | Secondary |
207P00000X | Emergency Medicine | 106567 (Missouri) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Missouri Baptist Medical Center | Town and country, MO | Hospital |
Memorial Hospital | Belleville, IL | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Washington University | 9830008770 | 2506 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company's pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.
Awareness and diagnoses of hypertension and diabetes in China has been limited, resulting in compromised treatment, and increased screening did not lead to significant improvements, according to a new study at Columbia University Mailman School of Public Health. Findings are online in the journal BMC Public Health.
The "personal incapacitant" spray or PIS is used for self defence in situations where "lethal force is inappropriate." It combines the compounds CS (o-Chlorobenzylidene malononitrile) with MiBK (Methyl isobutyl keton).
The Boston Globe: "A Suffolk Superior Court judge yesterday ordered two of the state's largest health insurers to submit April 2009 rates for insurance covering individuals and small businesses, the latest development in an ongoing dispute between the state and carriers over premium increases. Both companies said they would comply, even as they proceed with administrative appeals in an effort to charge higher rates.
Neurotech Pharmaceuticals, Inc., today announced that it was reported in the Proceedings of the National Academy of Sciences that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in a Phase 2 study.
› Verified 5 days ago
Entity Name | Washington University |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1104866656 PECOS PAC ID: 9830008770 Enrollment ID: O20040205000494 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company's pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.
Awareness and diagnoses of hypertension and diabetes in China has been limited, resulting in compromised treatment, and increased screening did not lead to significant improvements, according to a new study at Columbia University Mailman School of Public Health. Findings are online in the journal BMC Public Health.
The "personal incapacitant" spray or PIS is used for self defence in situations where "lethal force is inappropriate." It combines the compounds CS (o-Chlorobenzylidene malononitrile) with MiBK (Methyl isobutyl keton).
The Boston Globe: "A Suffolk Superior Court judge yesterday ordered two of the state's largest health insurers to submit April 2009 rates for insurance covering individuals and small businesses, the latest development in an ongoing dispute between the state and carriers over premium increases. Both companies said they would comply, even as they proceed with administrative appeals in an effort to charge higher rates.
Neurotech Pharmaceuticals, Inc., today announced that it was reported in the Proceedings of the National Academy of Sciences that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in a Phase 2 study.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Joseph L Galkowski, DO Po Box 60352, Saint Louis, MO 63160-0352 Ph: (314) 966-5000 | Dr Joseph L Galkowski, DO 3015 N Ballas Rd, Dept Emergency Med, Saint Louis, MO 63131-2329 Ph: (314) 966-5000 |
News Archive
Merrimack Pharmaceuticals, Inc. announced today that it will present pre-clinical data on MM-121 and MM-111, the two lead candidates in the company's pipeline of five novel cancer antibodies, at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held April 17 – 21, 2010, in Washington, D.C.
Awareness and diagnoses of hypertension and diabetes in China has been limited, resulting in compromised treatment, and increased screening did not lead to significant improvements, according to a new study at Columbia University Mailman School of Public Health. Findings are online in the journal BMC Public Health.
The "personal incapacitant" spray or PIS is used for self defence in situations where "lethal force is inappropriate." It combines the compounds CS (o-Chlorobenzylidene malononitrile) with MiBK (Methyl isobutyl keton).
The Boston Globe: "A Suffolk Superior Court judge yesterday ordered two of the state's largest health insurers to submit April 2009 rates for insurance covering individuals and small businesses, the latest development in an ongoing dispute between the state and carriers over premium increases. Both companies said they would comply, even as they proceed with administrative appeals in an effort to charge higher rates.
Neurotech Pharmaceuticals, Inc., today announced that it was reported in the Proceedings of the National Academy of Sciences that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) in a Phase 2 study.
› Verified 5 days ago
Sean Oliver Cavanaugh, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 660 S Euclid Ave # 8072, Washington University Emergency Medicine, Saint Louis, MO 63110 Phone: 314-362-9177 | |
John Verhey, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Barnes Jew Hosp Plz, Saint Louis, MO 63110 Phone: 314-362-9177 | |
Dr. Mackenzie Ann Mcknight, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1 Barnes Jew Hosp Plz, Saint Louis, MO 63110 Phone: 314-362-9177 | |
Nagla Abdelmalek, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 11133 Dunn Rd, Saint Louis, MO 63136 Phone: 314-653-5663 | |
Dr. Jose I Alvarez, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 6150 Oakland Ave, Saint Louis, MO 63139 Phone: 314-768-3090 Fax: 314-768-3031 | |
Addie Burtle, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110 Phone: 314-362-9177 | |
Dr. Opeolu Makanju Adeoye, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Barnes Jewish Hospital Plz, Dept Emergency Med, Saint Louis, MO 63110 Phone: 314-362-9123 Fax: 314-362-0478 |